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Background: Phenolic acids are covalently bound to the arabinoxylan fibre matrix of wheat aleurone layer. In order
to be bioavailable they need to be released by endogenous or bacterial enzymes and absorbed within the
intestinal lumen. The intestinal microbiota can metabolize phenolic acids and other food-born phytochemicals.
However, the effect of structure of the cereal bran or aleurone layer on these processes is not comprehensively
studied.
Methods: The structure of aleurone layer was modified either by dry-grinding or by enzymatic treatments with
xylanase alone or in combination with feruloyl esterase. Diet induced obese C57BL6/J mice were fed with high-fat
diets containing either pure ferulic acid, or one of the four differentially treated aleurone preparations for 8 weeks.
The diets were designed to be isocaloric and to have similar macronutrient composition. The urinary metabolite
profiles were investigated using non-targeted LC-qTOF-MS-metabolomics approach.
Results: The different dietary groups were clearly separated in the principal component analysis. Enzymatic
processing of aleurone caused increased excretion of ferulic acid sulfate and glycine conjugates reflecting the
increase in unbound form of readily soluble ferulic acid in the diet. The urinary metabolite profile of the diet groups
containing native and cryo-ground aleurone was more intense with metabolites derived from microbial processing
including hippuric acid, hydroxyl- and dihydroxyphenylpropionic acids. Furthermore, aleurone induced specific
fingerprint on the urinary metabolite profile seen as excretion of benzoxazinoid metabolites, several small
dicarboyxlic acids, and various small nitrogen containing compounds.
Conclusions: The structural modifications on wheat aleurone fraction resulted in altered metabolism of aleurone
derived phenolic acids and other phytochemicals excreted in urine of diet-induced obese mice.
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Whole grain consumption has been consistently related to
lower incidence of cardiovascular disease, obesity, diabetes,
and cancer in epidemiological studies [1,2]. In addition to
being excellent source of fibre, whole grains contain also
rich variety of bioactive secondary compounds produced
by the plant/grain [3]. These bioactive compounds are
mainly located in the outer membranes of the grain, which
are recovered in the bran during the milling process.
Aleurone is one of the outermost layers of the cereal
grain [4]. It is composed of one single layer of cells located
between the endosperm and seed coat. The main compo-
nent of wheat aleurone cell wall is arabinoxylan (AX),
which is a nonstarch polysaccharide constituted of a linear
backbone of beta-(1,4)-linked xylose residues that can be
substituted with one or two arabinose residues [5]. AX
makes the aleurone rich in dietary fibre (DF), but also rich
in bioactive phenolic compounds as the arabinose residues
of AX are generally highly substituted with phenolic acid
residues such as ferulic acid (FA), which is the major
phenolic acid present in the aleurone layer. These phen-
olic compounds have been suggested to play a role in the
beneficial health effects of diets rich in whole grain wheat
[2]. Ferulic acid (FA) is indeed mostly responsible for the
antioxidant effects of the wheat grain [6], and in particular
bran [7]. In addition to a wide variety of phenolic com-
pounds, the aleurone layer is a good source of minerals
and vitamins, which are located intracellularly [3].
Prior to reaching the circulation and being able to exert
its biological effects FA needs to be released from the sur-
rounding grain or tissue matrix either by the intestinal
mucosal enzymes or by the intestinal bacterial enzymes
[8,9]. However, the complex structure of the aleurone cell
layer can directly affect the bioaccessibility and further
bioavailability of FA [10] and other compounds travelling
through the digestive tract. This so called ‘matrix effect’
might have an influence on the physiological response to
the compounds bound to AX.
The bioaccessibility of phenolic compounds present in
wheat bran can be improved by reduction of particle size
(increasing the specific surface area) via ultra-fine grinding
and by solubilization of cell wall polysaccharides via en-
zymatic processing using xylanase and feruloyl esterases
[7,11,12]. Both increase of particle size and the enzymatic
release of FA moieties as free or conjugated to oligosac-
charides, were shown to improve the in vitro antioxidant
capacity as compared to the unprocessed aleurone [7,13]
suggesting that these modifications might also have differ-
ent bioeffects in vivo. However, there are no human or
animal studies so far investigating the effect of the matrix
structure on bioavailability of FA and other AX-bound
phytochemicals of aleurone layer. In the first part of this
study by Rosa et al. (Rosa N, Pekkinen J, Zavala K,
Fouret G, Ayhan Kormaz A, Feillet-Coudray C, Atalay M,Hanhineva K, Mykkänen H, Poutanen K, Micard V: En-
zymatic modification of wheat aleurone reduces body
weight and metabolic risk factors of obesity in mice fed a
high-fat diet. Submitted) we showed that enzymatically
processed aleurone layer with increased amount of free FA
produce beneficial health effects, i.e. reduced bodyweight,
adipose tissue amount and fasting insulin and leptin levels
in a high-fat diet induced obese mouse model. Here, in the
second part of the study, the aim was to analyze the urin-
ary metabolic fingerprint of the mice from the study by
Rosa et al. using non-targeted LC-qTOF-MS metabolo-
mics approach in order to elucidate the differences in bio-
available phytochemicals between the diets.
Methods
Wheat aleurone preparations and composition of diets
The wheat aleurone-rich fraction (A1) was provided by
Bühler AG (Uzwil, Switzerland). Its chemical composition
was 39.7 g dietary fibre, 22.2 g protein, 13.3 g ash, 9.8 g
fat, and 5.8 g starch in 100 g aleurone dry matter. The pro-
cessing of the aleurone was described in our previous
work [13]. Shortly, following treatments were applied on
the native aleurone (A1) to obtain three modified aleurone
preparations: ultra-fine grinding with an impact mill in
cryogenic conditions (A2), which produced an aleurone
fraction with smaller particle size (1/3 of the native one);
xylanase treatment (A3), which solubilized 43% of AX and
released 17% of FA in a bioavailable form (conjugated plus
free forms); successive xylanase and A-type feruloyl ester-
ase (FAE) treatments (A4) which solubilized 82% of AX
and released 87% of FA in bioavailable forms [14].
The details of the diets are described by Rosa et al.
(Rosa N, Pekkinen J, Zavala K, Fouret G, Ayhan Kormaz A,
Feillet-Coudray C, Atalay M, Hanhineva K, Mykkänen H,
Poutanen K, Micard V: Enzymatic modification of wheat
aleurone reduces body weight and metabolic risk factors of
obesity in mice fed a high-fat diet. Submitted). Shortly, all
the aleurone and commercial ferulic acid enriched diets
were designed to match the commercial D12451 standard
high-fat diet (45 E% of fat, Research Diets Inc., New Bruns-
wick, NJ, USA) with calorie density, amount of macronu-
trients, and with total fibre content. Approximately 13%
(w/w) of aleurone preparation (A1-A4) was added in the
diets during the cold extrusion process by the manufac-
turer (Research Diets Inc., New Brunswick, NJ, USA). The
energy and macronutrient distributions naturally present
in the aleurone preparations were taken into account
when planning the diets. Therefore, for instance, the total
protein amount in the final aleurone diets consisted of the
protein, naturally present in aleurone preparation and of
the added commercial protein source, casein. The amount
of commercial FA used in the FA control diet was de-
signed to be similar with the FA amount in the final A1
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ie. nothing was removed.
Animals and study design
The details of the study design and animal trial are
described by Rosa et al. (Rosa N, Pekkinen J, Zavala K,
Fouret G, Ayhan Kormaz A, Feillet-Coudray C, Atalay M,
Hanhineva K, Mykkänen H, Poutanen K, Micard V: Enzym-
atic modification of wheat aleurone reduces body weight
and metabolic risk factors of obesity in mice fed a high-fat
diet. Submitted). Shortly, C57BL/6 J male mice were ob-
tained from National Laboratory Animal Center (Kuopio,
Finland) at the age of 9 weeks. The mice were acclimatized
for one week and housed 3–4 per cage in regulated environ-
ment; temperature 22 ± 1°C, relative air humidity 55 ± 15%
and 12/12 h light/dark cycle with lights on at seven AM.
Due to increased occasions of fighting, the mice were sepa-
rated to single cages from the week 13 until the end of the
study (week 17). The mice were fed ad libitum a commer-
cial high-fat diet (D12451, Research Diets Inc., USA) during
weeks 1–9 to induce obesity and related metabolic disor-
ders. After HFD prefeeding the mice were randomized into
study groups (n = 9-14 per group) and were fed either with
D12451 (high-fat diet control, HFD) or the D12451 diets
enriched with aleurone fractions (A1-A4) or commercial FA
for additional 8 weeks. The animal experiment was ap-
proved by The Institutional Animal Care and Use Commit-
tee of the Provincial Government of Finland.
Urine sample preparation
Urine samples were collected on the week 17 directly into
microcentrifuge tubes while the animals were handled. The
number of urine samples per dietary group varied from two
to four. One sample consists of a pool of urine from 3–4
mice housed in the same cage during the study. The urine
samples were frozen on dry ice and stored at −80°C until
thawed on ice bath and filtered using 0.2 μm Acrodisc® Syr-
inge Filters with a PTFE membrane (PALL Corporation,
Ann Arbor, MI) prior subjecting to the LC-MS analyses.
LC-MS conditions
Urine samples were analysed with Agilent UHPLC-qTOF-
MS System using electrospray ionization (Jet Stream) in
negative polarity (Agilent Technologies 1290 LC, 6540
MS). Chromatographic separations were performed using
hydrophilic interaction chromatography (HILIC) with an
Acquity UPLC BEH Amide column (100 mm× 2.1 mm,
1.7 μm; Waters Corporation, Milford, MA). Column
temperature was 45°C, flow rate 0.6 ml/min, and the elu-
ents A and B were 50% (v/v) and 90% (v/v) acetonitrile, re-
spectively, both containing 20 mM of pH 3 ammonium
formate. The gradient was as follows: 0–2.5 min: 100% B;
2.5–10 min: from 100% to 0% B; 10–10.01 min: from 0%
to 100% B; 10.01–12.5 min: 100% B. Injection volume was2 μl and sample tray temperature 4°C. Acetonitrile was
from VWR International (Darmstadt, Germany). Ammo-
nium formate and formic acid were from Sigma (Sigma-
Aldrich, St. Louis, MO). All mobile phase constituents
were of LC-MS or LC-MS Ultra grade. Water was purified
using a Milli-Q Gradient system (Millipore, Milford, MA).
The ion source conditions were as follows: drying gas
temperature 325°C and flow 10 L/min, sheath gas
temperature 350°C and flow 11 L/min, nebulizer pressure
45 psi, capillary voltage 3500 V, nozzle voltage 1000 V, and
fragmentor voltage 100 V. For data acquisition, 2 GHz ex-
tended dynamic range mode was used with an abundance
threshold at 150, mass range of 20–1600, and scan time of
600 ms (1.67 Hz). For automatic MS/MS analyses, precur-
sor isolation width was 1.3 Da, and from every precursor
scan cycle, 4 ions with the highest intensity were selected
for fragmentation. These ions were excluded after 2 prod-
uct ion spectra and released after a 0.25-min hold. Precur-
sor scan time was based on ion intensity, ending at 20000
counts or after 500 ms. Product ion scan time was 500 ms.
Collision energies were 10, 20 and 40 V in subsequent
runs. Continuous mass axis calibration was performed by
monitoring two reference ions from an infusion solution
throughout the runs (m/z 112.985587, m/z 966.000725).
Data acquisition software was MassHunter Acquisition
B.04.00.
Non-targeted metabolomics data processing
Initial data processing was performed using MassHunter
Qualitative AnalysisB.05.00 (Agilent Technologies, USA).
Ions were extracted to compounds exhibiting isotopic
peaks, dimers, and common adducts. The data were out-
put as compound exchange format (.cef files) into the
Mass Profiler Professional (MPP) software (version 2.2,
Agilent Technologies) for compound alignment, statistical
evaluation (ANOVA, student’s t-test), and chemometrics
analysis by principal component analysis (PCA). In order
to reduce noise and low abundance metabolites from the
data matrix, only the metabolite features that appeared in
at least 60% of samples in at least one of the dietary condi-
tions having abundance at least 4.0E + 04 were retained in
the data matrix, resulting in a dataset containing 3082 me-
tabolite features. For PCA analyses, metabolite features
were further filtered to satisfy a corrected q-value cut-off
0.05 (ANOVA, Benjamini-Hochberg false discovery rate
correction for p-values) resulting in 662 entities. For the
pairwise comparison of the diet groups, the data matrix
(3082 features) was exported to Excel and filtered accord-
ing to the abundance (n = 3 at least in one condition of FA
or A1-A4), maximum average >4.0E + 05 in any of the
groups FA or A1-A4 (in order focus on the most abundant
peaks amenable for MS/MS fragmentation), q-value <0.05
(pairwise t-test with Benjamini-Hocberg FDR correction),
and fold change >3.0 in any of the groups FA or A1-A4
Figure 1 Principal component analysis (PCA) of the urinary
metabolite features resulting from HILIC chromatography
combined with ESI(−)qTOF-MS non-targeted metabolite profiling.
Diet induced obese mice were fed with high-fat control diet (HF), or
with HF diet containing either free commercial ferulic acid (FA) or
one of the four differently processed aleurone preparations (A1-A4).
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entities that were further reduced to 50 metabolites after
cleaning the data from fragments and dimers of the mo-
lecular ions, from entities having high (>20%) RSD values
in more than 3 out of 6 conditions, peaks with bad quality,
or entities with clearly integration mistakes. The final set
of metabolites was identified based on the auto MS/MS
data or within targeted MS/MS analysis for extracted ions.
The fragmentations were compared against The METLIN
Metabolite Database (http://metlin.scripps.edu/), Human
Metabolome Database (HMDB, www.hmdb.ca/), or earlier
published fragmentation patterns, and verified with com-
mercial standards when available. Bar chart results are
expressed as means ± SEM of peak area abundances
(GraphPad Prism Version 5.03). K-means clustering ana-
lyses were used for further visualization of the final set of
50 metabolites by using Multi Experiment Viewer, MeV
(version 4.8.1) (http://www.tm4.org/). The raw data was
imported to MeV and the data were normalized in row-
wise manner aiming at comparing the metabolite inten-
sities between different samples (Value = [(Value) – Mean
(Row)]/[Standard deviation(Row)]). The normalized data
were then clustered into three K-means clusters according
to metabolites using a Pearson correlation as a distance
metric method with maximum of 50 iterations.
Results and discussion
Principal component analysis of the dataset containing
ANOVA-filtered metabolite entities (q < 0.05) showed
clear clustering of the biological sample replicates close
to each other with clear separation between the dietary
groups (Figure 1). The principal component 1 (46.78%)
explains the largest variation in the plot referring mainly
to the difference caused by the addition of the processed
aleurone preparations to the diet. We further narrowed
the dataset to only focus on the highly abundant metab-
olites amenable for MS/MS structural investigation that
were significantly increased (q < 0.05, fold change >3)
after adding FA or one of the aleurone preparations into
the diet when compared to HF control diet. This resulted
in 50 metabolites (Table 1). These metabolites were classi-
fied into three different clusters according to the occur-
rence of the metabolite signal in the different groups by
using K-means cluster analysis (Figure 2).
Majority of free ferulic acid was excreted as sulfate or
glycine conjugates
The cluster 1 includes metabolites that were highly
increased after adding FA into the diet for 8 weeks (fold
change to HF control was between 421 and 4.5-fold)
(Figure 2). By comparing the MS/MS fragmentation
data with those given in public databases (METLIN,
HMDB) or with the unconjugated standard compounds
these metabolite signals in the cluster 1 were identifiedto be two different isomers of ferulic acid sulfates (m/z
273.0075), unidentified m/z 246.9918, glycine conjugate
of ferulic acid (feruloylglycine, m/z 250.0711), glycine
conjugate of vanillic acid (vanilloylglycine m/z 224.0554),
dihydroferuloylglycine (m/z 252.0874), and 2,6- dihydroxy-
benzoic acid sulfate (m/z 232.9763, (Figure 3, Table 1).
Majority of the metabolites in the cluster 1 seem to be
well-known endogenous metabolites of rapidly absorbed
FA. FA sulfate has been identified as major dietary FA me-
tabolite recovered in urine in rats [20-23]. Previous in vivo
studies have shown that free dietary FA is rapidly absorbed
in the upper parts of the intestine and conjugated mainly
in the liver either into its phase II metabolites, mainly
sulfonate or glucuronide conjugates and further excreted
in urine [22]. A small proportion of ingested free FA may
also be metabolized through beta-oxidation in liver to
form vanillic acid, or through phase I metabolism into
dihydroferulic acid and different forms of dihydroxyben-
zoic acids [20,24,25]. Notably, the cluster 1 was particu-
larly rich in glycine conjugated metabolites.
The FA diet contained pure FA added to the food mass
and was thus in free form which allows the solubilization
and absorption from the upper parts of the intestine.
However, this is not the case with more complex bio-
logical matrices. In the unprocessed aleurone FA is cova-
lently bound to the arabinoxylan and the complex
structure of the aleurone does not allow absorption of FA
[10]. Therefore, prior to reaching the circulation FA moi-
eties need to be released from the surrounding tissue
matrix either by the intestinal mucosal enzymes or by the
intestinal bacterial enzymes, in order to be bioavailable for
Table 1 Complete list of metabolites
MS m/z(−) Retention
time




MM Cluster Ref./Metlin ID
188.0023 0.63 188.0023 [M-H]- 10ev: 188.0025 [M-H]- (100), 79.9574 [SO3]- (74),
108.0456 [M-H-SO3]- (59), 80.9657 (3)
2-Aminophenol sulfate C6H7NO4S 189.0103 Cluster 2 [15]
258.9908 0.65 258.9908 [M-H]- 20ev: 179.0351 [M-SO3]- (100), 135.0451 [M-SO3-COO]- (95),
96.9609 [HSO4]- (5), 135.0941 (2)
Caffeic acid sulfate C9H8O7S 260.00 Cluster 3 [16]
261.0061 0.65 261.0061 [M-H]- Unknown M- [261.0061] rt 0.65 262.0141 Cluster 2 N.I.
273.0074 0.65 273.0075 [M-H]- 10ev: 193.0508 [M-H-SO3]
- (100), 273.0076 [M-H]- (33),
178.0266 [M-H-SO3-CH3]- (7), 149.0604 [M-H-SO3-COO]- (6), 96.9598 [HSO4]- (5),
193.1079 (5), 134.0365 (5), 229.0171 (3), 79.9571 [SO3]- (1)
Ferulic acid sulfate
(3- or 4-sulfate) - FA sulfate
C10H10O7S 274.0154 Cluster 1 [16]
245.012 0.66 245.0144 [M-H]- 10ev: 245.0119 [M-H]- (100), 165.0547 [M-H-SO3]- (34),
121.065 [M-H-SO3-COO]- (10), 245.0757 (4), 79.957 [SO3]- (2)
3-or 4-Hydroxyphenylpropionic
acid sulfate - HPPA-sulfate
C9H10O6S 246.02 Cluster 2 MID 4152
275.023 0.67 275.0237 [M-H]- 20ev: 195.0664 [M-H-SO3]- (100), 59.0138 (54), 79.9582 [SO3]- (31),
136.0526 (25), 275.024 [M-H]- (14), 151.0755 [M-H-SO3-COO]- (7)
Dihydroferulic acid sulfate C10H12O7S 276.031 Cluster 2 [16]
206.0811 0.73 206.0838 [M-H]- 10ev: 74.0251 [Glycine-H]- (100), 206.0817 [M-H]- (36),
162.0925 [M-H-COO]- (9), 131.0502 [M-glycine]- (3), 126.0264 (3)
Unknown glycine conjugate
M- [206.0838] rt 0.73
C11H13NO3 207.0891 Cluster 2 N.I.
273.0075 0.79 273.0075 [M-H]-10ev: 193.0508 [M-H-SO3] (100), 273.0075 [M-H]
- (42),
96.9608 [HSO4]
- (9), 149.0603 [M-H-SO3-COO] (9), 178.0272 (8)
Ferulic acid sulfate
(3- or 4-sulfate) - FA sulfate
C10H10O7S 274.0155 Cluster 1 [16]
204.0668 0.80 204.0667 [M-H]- 10ev: 160.0768 [M-H-COO]- (100), 130.0663 [M-H-C2H4NO2]- (37),
204.0667 [M-H]- (29), 103.0552 [M-C3H3NO3]- (27), 117.0707 (8), 132.0822 (6),
82.0288 (4)
Cinnamoylglycine C11H11NO3 205.0748 Cluster 2 MID 34534
245.0118 0.80 245.0144 [M-H]- 10ev: 245.0119 [M-H]- (100), 165.0547 [M-SO3]- (30),
121.065 [M-H-SO3-COO]- (11), 74.0241 (8), 79.957 [SO3]- (2), 201.1035 [M-H-COO]- (2)
3-or 4-Hydroxyphenylpropionic
acid sulfate - HPPA-sulfate
C9H10O6S 246.0198 Cluster 2 MID 4152
275.0232 0.83 275.024 [M-H]- 10ev: 275.024 [M-H]- (100), 195.066 [M-H-SO3]- (41), 193.051 (12),
79.9582 [SO3]- (8), 59.0138 (2), 136.054 (2), 80.9653 (2), 151.076 [M-H-SO3-COO]- (1),
149.061 (1), 123.045 (1)
Dihydroferulic acid sulfate C10H12O7S 276.0312 Cluster 2 [16]
232.9763 0.93 232.976 [M-H]- 20ev: 153.0193 [M-H-SO3]- (100), 109.0294 (90.24), 135.0446 (14.23),
96.9596 [HSO4]- (5.32), 123.0434 (2.33), 61.9895 (2.23), 232.975 [M-H]- (2.12)
2,6-Dihydroxybenzoic acid
sulfate - 2,6-DHBA sulfate
C7H6O7S 233.9843 Cluster 1 [17]
246.9918 0.99 246.9918 [M-H]- 10ev: 167.0354 [M-H-SO3]
- (100), 152.0118 (88), 123.0118 (41),
108.0218 (25), 96.906 [HSO4]- (9), 152.0639 (6), 79.9581 [SO3]- (4)
Vanillic acid sulfate C8H8O7S 247.9998 Cluster 1 Manual
178.0507 1.05 178.0521 [M-H]- 10ev: 134.0612 [M-H-COO]- (100), 178.0511 [M-H]- (85.7),
77.0401 [M-H-C3H3NO3]- (41.4), 56.0147 (6.0)
Hippuric acid C9H9NO3 179.0587 Cluster 2 MID 1301
277.0379 1.07 277.0379 [M-H]- 20ev: 197.0811 [M-H-SO3]- (100), 182.0574 [M-H-SO3-CH3]- (59),
79.9577 [SO3]- (29), 197.0453 (20), 125.0608 [C7H9O2] (20), 277.0371 [M-H]- (18),
122.036 (16),
Unknown sulfonated metabolite
M- [277.0379] rt 1.071
278.0459 Cluster 2 N.I.
261.0075 1.17 261.0081 [M-H]- 20ev: 137.061 (100), 181.0504 [M-SO3]- (14), 261.0072 [M-H]- (13),




C9H10O7S 262.0155 Cluster 2 Unconjugated
std.
305.0331 1.18 305.0343 [M-H]- 20ev: 225.0783 [M-H-SO3]- (100), 59.0147 (90), 79.9572 [SO3]- (48),
166.0626 (36), 80.9651 (13), 149.0605 (12), 165.0567 (12),
153.0552 (8), 305.0386 [M-H]- (8)
Unknown sulfated metabolite
M- [305.0331]- rt 1.18




















Table 1 Complete list of metabolites (Continued)
258.9917 1.22 258.9926 [M-H]- 20ev: 179.0352 [M-H-SO3]- (100), 135.045 [M-SO3-COO]- (9),
91.0553 [C7H7]- (5), 258.9926 [M-H]- (4), 93.0357 [C6H5O]- (3)
3- or 4-Caffeic acid sulfate C9H8O7S 259.9997 Cluster 2 [16]
252.0874 1.23 252.0896 [M-H]-10ev: 74.0255 [C2H4NO2]- (100), 252.0889 [M-H]- (74),
193.0769 [C10H9O4]- (10), 177.0554 [M-H-glycine]- (8)
Dihydroferuloylglycine C12H15NO5 253.0954 Cluster 1 Manual
250.0711 1.32 250.0711 [M-H]- 10ev: 100.0035 (100), 149.0608 (91), 250.072 [M-H]- (80),
206.0828 [M-H-COO]- (68), 134.0377 (68), 163.0637 (29), 191.9576 (22),
175.0545 (20), 177.0545 (19)
Feruloylglycine C12H13NO5 251.0791 Cluster 1 [16]
320.0436 1.42 320.0436 [M-H]- 20ev: 230.0134 [M-H-C3H6O3]- (100), 150.0557 [M-H-C3H6O3-SO3]-





C11H15NO8S 321.0516 Cluster 3 HPAA std.
224.0554 1.50 224.0566 [M-H]- 10ev: 100.0042 [C3H2NO3]
- (100), 224.0566 [M-H]- (38), 123.0449
[C7H7O2]- (31), 74.0230 (12), 180.0646 [M-H-COO]- (9), 165.0402 [M-H-COO-CH3]- (7)
Vanilloylglycine C10H11NO5 225.0634 Cluster 1 [18]
258.9908 1.84 258.9938 [M-H]- 10ev: 215.0026 [M-H-COO]- (100), 135.045 [M-H-COO-SO3]- (22),
240.9815 [M-H-H2O]- (7), 161.0245 (6), 258.9934 [M-H]- (0.4)
Unknown M- [258.9938] rt 1.84 C9H8O7S 259.9988 Cluster 2 N.I.
305.033 1.86 305.0354 [M-H]- 20ev: 123.0452 (100), 101.0244 (83), 163.0763 (62),
305.0354 [M-H]- (61), 207.0688 (8) [M-H2O-sulfate], 79.9573 [SO3]- (7),
96.9606 [HSO4]- (6), 287.0189 [M-H2O]- (2)
Genipin sulfate C11H14O8S 306.041 Cluster 2 [19]
161.0449 2.02 161.0450 [M-H]- 10ev: 57.0348 [C3H5O]- (100), 99.0453 [C5H7O2]- (80),
101.0241 [M-H-C2H4O2]- (40), 161.045 [M-H]- (29), 59.0144 (11)
3-hydroxy-3-methyl-glutaricacid -
HMGA
C6H10O5 162.0529 Cluster 2 MID 3793
186.0765 2.63 186.0765 [M-H]- 10ev: 114.0927 [M-H-C2CO3]- (100), 142.0866 [M-H-COO]- (54),
186.0779 [M-H]- (52), 58.03 [C2H4NO]- (39), 100.0757(37), 68.0508 [C4H6N]- (18)
Unknown N-containing
metabolite M- [186.0765] rt 2.63
C8H13NO4 187.0845 Cluster 3 N.I.
229.1184 2.64 229.1184 [M-H]- 10ev: 229.1179 [M-H]- (100), 187.1077 [M-H-C2H2O]- (86),
58.0301 [C2H4NO] (13), 145.0978 [C6H13N2O2]- (12), 143.1194(12)
Unknown N-containing
metabolite M- [229.118] rt 2.64
C10H18N2O4 230.1264 Cluster 3 N.I.
232.9762 2.67 232.9779 [M-H]- 20ev: 153.0195 [M-H-SO3]- (100), 109.0297 [M-H-SO3-COO]- (29),
65.0405 (21), 67.0198 (12), 232.9776 [M-H]- (4)
3,5-dihydroxybenzoic acid
sulfate - 3,5-DHBA sulfate
C7H6O7S 233.9842 Cluster 3 Unconjugated
std./[17]
392.1382 2.70 392.1382 [M-H]- 20ev: 124.0071 (100), 348.1493 [M-H-COO]- (54), 146.8045 (6),
79.9583 [SO3]- (3), 149.9861 (3)
Unknown metabolite
M- [392.1382] rt 2.70
C16H27NO8S? 393.1462 Cluster 3 N.I.
270.9754 2.81 270.9754 [M-H]- 20ev: 96.9602 [HSO4]- (100), 97.0011 (2), 79.9562 [SO3]- (2),
112.987 (1), 270.9775 (1)
Unknown sulfate containing
metabolite M- [270.9754] rt 2.8
C6H8O10S? 271.9834 Cluster 2 N.I.
202.0709 2.85 202.0709 [M-H]- 10ev: 202.0721 (M-H]- (100), 88.0405 [C3H6NO2] (80),
158.0818 [M-H-COO]- (56), 86.0615 (54), 87.0451 [C4H8NO] (43), 114.0194 (26),
184.0607 [M-H-H2O]- (24), 140.0706 [C7H10NO2]- (14), 70.6966 (7), 132.0306 (6)
Unknown N-containing
metabolite M- [202.0709] rt 2.85
C8H13NO5 203.0789 Cluster 3 N.I.
246.9906 2.85 246.9931 [M-H]- 10ev: 167.0356 [M-SO3]- (100), 246.9931 [M-H]- (44),
123.0458 [M-SO3-COO]- (13), 96.9607 [HSO4]- (8), 152.0123 [M-SO3-COO-CH3]- (8),
203.0024 (7), 167.0923 (6), 79.9581 [SO3]- (3)
3,5-Dihydroxyphenyl acetic acid
sulfate - 3,5-DOPAC sulfate
C8H8O7S 248.00 Cluster 3 Unconjugated
std.
347.1341 2.86 347.1370 [M-H]- Unknown glucuronidated
metabolite M- [347.1370-
glucuronide – > 171.1031]
C15H24O9 348.1421 Cluster 3 N.I.
215.1028 2.91 215.1028 [M-H]- 20ev: 173.0925 [M-H-C2H2O]- (100), 58.03 [C2H4NO]- (51),
44.0145 (42), 143.1179 (24), 129.1032 (11), 126.0921 (6), 172.1036 (3)
Unknown N-containign
metabolite M- [215.103] rt 2.91
C9H16N2O4 216.1108 Cluster 3 N.I.
174.0763 2.95 174.0763 [M-H]- 10ev: 74.025 [glycine]- (100), 174.0766 [M-H]- (42), 100.0758
[M-H-C2H2O3]- (12), 128.0703 (11), 112.0374 (10), 130.085 (9), 132.067 (5), 59.0132 (4)
Unknown N-containign
metabolite M- [174.0763]




















Table 1 Complete list of metabolites (Continued)
334.1322 2.99 334.1322 [M-H]- Unknown metabolite
M- [334.132] rt 2.99
C14H25NO6S? 335.1402 Cluster 3 N.I.
139.9835 2.99 139.9859 [M-H]- 10ev: 95.9344 [M-H-COO]- (100), 139.9842 [M-H]- (94),
76.0225 [C2H6NS]- (5), 96.9419 (3), 95.9763 (2), 140.0336 (2)
Unknown sulfate containing
metabolite M- [139.9859] rt 2.99
? 140.9915 Cluster 3 N.I.
216.0868 3.01 216.0868 [M-H]- 10ev: 128.0342 (100), 172.0965 [M-H-COO]- (90), 216.0872 [M-H]- (87),
198.0769 [M-H-H2O]- (31), 102.0566 (28), 128.1066 (26), 87.0459 (21), 86.0603 (20),
98.06 (12), 154.0854 (12)
Unknown N-containing
metabolite M- [216.0868] rt 3.01
C9H15NO5 217.0948 Cluster 3 N.I.
347.1343 3.04 347.1370 [M-H]- 10ev: 113.0247 [fragment of glucuronide] (100),
171.1031 [M-glucuronide]- (85), 347.1361 [M-H]- (30), 85.0294 [fragment of
glucuronide] (25), 175.0247 (23), 59.0146 (20), 95.0132 (13)
Unknown glucuronidated
metabolite [m/z 171.1023 +
glucuronide]
C15H24O9 348.1423 Cluster 3 N.I.
166.0169 3.13 166.0169 [M-H]- 20ev: 79.9578 [SO3]- (100), 166.0167 [M-H]- (28), 106.9804 (25),
100.0411 (13), 80.9651 (9), 58.0295 (5)
Unknown M- [166.017] rt 3.13 C4H9NO4S 167.0249 Cluster 3 N.I.
149.0446 3.14 149.0466 [M-H]- Tentative sugar either
arabinose, xylose, or ribose
C5H10O5 150.0526 Cluster 3 N.I.
144.0768 3.94 144.0790 [M-H]- 10ev: 102.0564 [M-H-CH2N2]- (100), 83.0619 (12),
84.0453 [M-H-COO-NH3]- (7), 58.0415 [C3H6O]- (6), 144.0778 [M-H]- (5), 102.099 (2)
4-Guanidinobutanoic acid C5H11N3O2 145.0848 Cluster 2 MID 4155
202.0709 4.10 202.0733 [M-H]- 10ev: 140.0716 (100), 158.0824 [M-H-COO]- (99), 202.0724 [M-H]- (93),
58.0297 [C2H4NO]- (50), 100.0401 [C4H6NO2]- (49), 116.069 (33), 69.0364 (31),
98.0612 (31), 110.0603 (28), 75.7348 (24), 345.1717 (12), 176.0227 (12)
Unknown N-containing
metabolite M- [202.071] rt 4.10
C8H13NO5 203.0789 Cluster 2 N.I.
159.0291 4.33 159.0291 [M-H]- Unknown M- [159.0291] rt 4.33 C6H8O5 160.0371 Cluster 2 N.I.
175.0238 4.66 175.0238 [M-H]- 10ev: 157.0134 [M-H-H2O]- (100), 87.0453 [C4H7O2]- (28),
175.0249 [M-H]- (20), 132.0666 [M-H-CH3CO]- (16), 69.0346 (15)
Unknown tentative dicarboxylic
acid
C6H8O6 176.0318 Cluster 2 N.I.
145.0139 4.67 145.0139 [M-H]- 10ev: 101.0246 [M-H-COO]- (100), 57.0348 [C3H5O]- (25),
145.0135 [M-H]- (16), 73.0296 [C3H5O2]- (5)
2-Oxoglutaric acid C5H6O5 146.0219 Cluster 2 MID 119
133.014 4.70 133.014 [M-H]- 10ev: 115.0036 [M-H-H2O]- (100), 71.014 [C3H3O2]- (60),
133.014 [M-H]- (38), 72.993 [C2HO3]- (16), 89.0246 [M-H-COO]- (9), 87.0077 (2),
44.9976 (2)
Malic acid C4H6O5 134.022 Cluster 3 MID 118
145.0135 5.05 145.0135 [M-H]- 10ev: 101.024 [M-H-COO]- (100), 57.0352 [C3H5O]- (97),
145.0116 [M-H]- (26), 82.028 (6), 127.0225 [M-H-H2O]- (6)
3-Oxoglutaric acid C5H6O5 146.0215 Cluster 3 Manual
147.029 5.19 147.029 [M-H]- Undientified M- [147.029] C5H8O5 148.037 Cluster 2
357.0826 5.59 357.0855 [M-H]- 10ev: 357.0843 [M-H]- (100), 113.0237 [fragment of glucuronide]- (58),
181.0518 [M-H-glucuronide]- (13), 137.0596 [M-H-glucuronide-COO]- (10),
175.0238 (10), 59.0138 (10), 85.0287 [fragment of glucuronide]- (6)
Glucuronidated 3,4- or 3,5-
Dihydroxyphenylpropionic acid,
DHPPA-glucuronide




















Figure 2 K-means clustering analysis on the 50 significantly increasing (q < 0.05) urinary metabolite features after adding FA or one of
the aleurone preparations (A1-A4) into the diet when compared to HF control diet. The signal abundances were row-wise normalized and
classified into three different clusters. The color-coding scale indicates the abundance within each metabolite: blue: low abundance, yellow: high
abundance, gray: not detected. Each replicate is a pool of 2–3 mice on the same diet group.
Figure 3 The urinary metabolites found in the cluster 1. A: Compounds that were highly increased in urine of mice fed either free
commercial ferulic acid (FA) or one of the four differently processed aleurone preparations (A1-A4) but were not present in the in the HF control
group. B: compounds that were increased duoe to the test diets, but had also high basal abundance in the HF control group. 1. 3- or 4-ferulic
acid sulfate, 2. 3- or 4-ferulic acid sulfate, 3. feruloylglycine, 4. vanilloylglycine, 5. dihydroferuloylglycine, 6. vanillic acid sulfate, and 7. 2,6-DHBA
sulfate.
Pekkinen et al. Nutrition & Metabolism 2014, 11:1 Page 8 of 15
http://www.nutritionandmetabolism.com/content/11/1/1
Pekkinen et al. Nutrition & Metabolism 2014, 11:1 Page 9 of 15
http://www.nutritionandmetabolism.com/content/11/1/1the circulation and human tissues thereafter, to exert any
potential bioactivity on cellular metabolism [8,9]. There-
fore, attempts have been made to improve the bioavailabil-
ity of FA by different bioprocessing techniques, such as
fermentation or enzymatic treatments of cereal grain, bran
or aleurone matrices [7,12-14]. Interestingly, the A4 diet
(xylanase and A-type feruloyl esterase treatment) pro-
duced a similar excretion profile of the main liver phase II
metabolites of FA, especially of FA sulfates, as the diet
containing free FA but in lower abundance (Figure 3). Fur-
thermore, the urine of the mice in A4 group displayed
clearly different excretion pattern of FA metabolites than
the other aleurone groups A1-A3, suggesting that the bio-
availability of FA in A4 group was, indeed, improved. The
diet containing aleurone treated only with xylanase (A3)
also generated increased free FA and FA linked to oligo-
saccharides (42% of total FA), and there was a tendency of
increased urinary excretion of the major FA metabolites
found in the cluster 1 (Figure 3A). The resemblance of FA
related metabolite profile (cluster 1) between A4 and FA
groups is not surprising since the combination of xylanase
and feruloylesterase treatment resulted in an increased
amount of FA moieties released in free form or as conju-
gated to oligosaccharides (85% of total FA) in the A4
aleurone fraction and the A4 diet [14]. Previous in vitro
studies have also suggested that enzymatic treatments by
xylanase combined or not with feruloylesterase could im-
prove the bioavailability of FA from the aleurone layer
[13]. Here we show for the first time that an enzymatic
modification applied to aleurone layer can affect also
in vivo metabolism of FA, the main phenolic acid present
in the aleurone.
The most intense metabolite signal in the cluster 1
was the m/z of 246.9918. The MS/MS analyses created
fragments that have been reported for both dihydroxy-
phenylacetic acid sulfate (DOPAC sulfate) and vanillic
acid sulfate [26,27]. The further analysis with commer-
cial standard compounds (vanillic acid, DOPAC) sug-
gested that the compound is rather vanillic acid sulfate
than DOPAC sulfate according to their fragmentation
patterns. Even though these two compounds share simi-
lar fragments (167.0352 [M-H-sulfate]-, 123.0453), it is
most likely that the fragments of 108.0218 and 152.0115
distinguish between these two compounds (Additional
file 1).
Tentatively identified DHBA-sulfate of the cluster 1
metabolites was also detected in high abundance in the
HF control group, suggesting that there are also other
dietary factors that might influence the high basal excre-
tion of this metabolite. The MS/MS fragmentation of
the DHBA sulfate (m/z 232.9763) created a fragment ion
of m/z 135.0195, which has been suggested to derive
only from the 2,6-configured DHBA (γ-resorcylic acid)
[17]. This metabolite has been reported as a significantplasma marker of fibre intake in a 5-weeks human inter-
vention, and has been suggested to be originated from
the alkylresorcinols after microbial metabolization [17].
However, our results suggest that the source of 2,6-
DHBA might be the phenolic acids, naturally present
within the diet as this form of DHBA was mainly
excreted in urine after addition of FA into the diet. The
colonic bacteria are capable of reconfiguring the phen-
olic hydroxyl substitutions, and it is possible that part of
the free FA can escape absorption and end up to the
distant parts of the intestine for microbial metabolism.
Furthermore, the 3,5-DHBA having different hydroxyl
group configuration is better described as the alkylresorci-
nol intake biomarker [28], and it was located into cluster 3
in our study.
Native and cryoground aleurone increased the excretion
of microbial phenolic metabolites
The majority of the urinary metabolites found in cluster
2 are metabolites that have highest abundance in urine
of the groups receiving either the native (A1) or ultra-fine
ground (A2) aleurone preparation (Figure 2). Interestingly,
several of these metabolite features seem to be increased
especially in the A2 group (Figures 2 and 4). Furthermore,
these metabolites are excreted with a higher abundance
in the dietary groups receiving native, cryoground, or
xylanase processed aleurone (A1-A3) than in the group
receiving xylanase and feruloylesterase processed aleur-
one (A4) (Figure 4). Among others, the metabolite sig-
nals in the cluster 2 included tentatively identified
negative ions of m/z 261.0075 (dihydroxyphenylpropionic
acid sulfate; DHPPA sulfate), m/z 178.0507 (hippuric acid),
m/z 245.0116 in two isomers (hydroxyphenylpropionic
acid sulfate; HPPA sulfate), m/z 204.0668 (cinnamoyl-
glycine), m/z 275.0232 in two isomers (dihydroferulic
acid sulfate), m/z 188.0023 (aminophenol sulfate), m/z
258.9908 (caffeic acid sulfate), m/z 357.0826 (DHPPA
glucuronide), and m/z 305.0331 (unknown) (Figure 4,
Table 1). DHPPA sulfate and hippuric acid were the me-
tabolites with the highest signal abundance in this cluster
(Figure 4B). All of these compounds have been identified
in human studies and in rodent models as microbial-
co-metabolites of phenolic compounds [28-31].
Phenolic acids including FA are well-known to face
microbial metabolism when they travel along the intes-
tinal tract to the lower parts including caecum (in rodents)
and colon. For instance, the double-bond of propenoic
acid side chain of FA can be first reduced to form dihy-
droferulic acid [16], and then further demethylated and
dehydroxylated, to form different forms of dihydroxy-,
hydroxyl-, or phenylpropionic acids (DHPPA, HPPA or
PPA) by the intestinal microbial enzymes (Figure 5)
[12,20,30,32]. These metabolites can be further degraded
either by the microbial enzymes or by endogenous phase I
Figure 4 The urinary metabolites from the cluster 2. A: 1. 3- or 4-HPPA sulfate, 2. 3- or 4-HPPA sulfate, 3. cinnamoylglycine, 4. 3 or
4-dihydroferulic acid sulfate, 5. 3- or 4-dihydroferulic acid sulfate, 6. aminophenolsulfate, 7. 3 or 4-caffeic acid sulfate, 8. m/z 258.99,
9. glucuronidated DHPPA, 10. tentative dihydrosinapic acid sulfate. B: 11. DHPPA sulfate and 12. hippuric acid (note the different scale).
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with glycine in liver to form hippuric acid [33].
The tentatively identified cinnamoylglycine was espe-
cially highly increased in the A2 group but also, inter-
estingly, in the FA group (3-fold). However, there are
not many studies published about cinnamoylglycine so
far. This might be partly because of species specific
differences regarding the cinnamoylglycine production,
as this metabolite has been detected in urine of mice
but not in rats [34].
Notably, in addition to FA, the aleurone layer contains
also other but minor phenolic compounds, including
sinapic acid and p-coumaric acid [35], which might con-
tribute to the increased excretion of the microbial me-
tabolites of phenolic compounds in the A1-A4 groups
when compared to the FA control group. In addition,
one of the unidentified metabolites m/z 305.0331, which
was only detected in the urine of mice receiving aleur-
one, might indeed be sulfonated dihydrosinapic acid, ori-
ginating from the sinapic acid (metabolite 10 in Figure 4)
(Additional file 1).
Altogether, these results suggest that ferulic acid as
well as other phenolic compounds mainly bound to the
arabinoxylan in the native and cryo-ground aleurone, are
intensively metabolized upon their release within the in-
testine (caecum, colon) by the action of intestinal micro-
biota (Figure 5). Therefore, the microbial metabolism
could change the fate of the bioactive phytochemicals
present in the aleurone similarly as previously shown withdifferent unprocessed and bioprocessed brans [29,36,37].
Whereas, in the case of enzymatically processed A4, the
majority of the FA is clearly absorbed already in the upper
part of the GI tract and the following metabolism of FA
prior to excretion in urine is mainly dependent on the
endogenous phase I and phase II metabolism (Figure 5).
Aleurone addition increased excretion of small
dicarboxylic acids
Interestingly, the cluster 2 contained also a set of metabo-
lites sharing similar molecular structure. Two of those
were identified as 2-oxoglutaric acid (m/z 145.0135) and
3-hydroxy-3-methyl-glutaric acid (HMGA) m/z 161.0449
(Figure 6). Additionally, metabolite features of m/z 147.029,
159.0291, and 175.0238 shared common fragmentation
pattern (Table 1). These urinary metabolites might be de-
rived from the aleurone matrix as several dicarboxylic
acids such as malic acid, succinic acid, fumaric acid, and
azelaic acid are naturally found in wheat and other grains
[38]. Alternatively, they may reflect changes in endogen-
ous metabolism as small organic acids are also naturally
present in the human urine [39]. All the metabolites seem
to have 4 to 6 carbon backbone, carboxyl groups at the
both ends of the molecule, and one or additional oxygens
(hydroxyl or acetone) attached to the carbon backbone
similarly as several citric acid cycle metabolites. Addition-
ally, two of the dicarboxylic acids were found also in clus-
ter 3, namely malic acid (m/z 133.014) and a different
isomer of oxoglutaric acid (m/z 145.0135) that could be be
Figure 5 Schematic presentation on the effect of aleurone structure on ferulic acid absorption from the different diets. 1. Free FA (a) is
readily absorbed to the portal vein from the stomach and upper parts of the intestine. In the diet A4 majority of FA is in free form due to
xylanase and feruloylesterase pretreatments. 2. The diet A3 contains xylanase treated aleurone and has a mixture of both free and bound FA and
is therefore in brackets. Whereas, in the diets containing intact (A1) or cryo-ground aleurone (A2) majority of FA is tightly bound to the arabinoxylan
fibre matrix, and bioavailability of FA is thus dependent on its release by the microbial enzymes within the caecum (mice) and colon. 3. Most of the
microbially released FA is further metabolized by the microbial enzymes. The modifications include reduction of FA into dihydroferulic acid (b), further
demethylation to form dihydroxyphenylpropionic acid (DHPPA) (c), dehydroxylation into hydroxyphenylpropionic acid (HPPA) (d), and finally
after another dehydroxylation step and beta-oxidation to benzoic acid (e). All of these intermediate metabolites can be absorbed to circulation,
however, part of them are excreted in faeces. 4. All the absorbed compounds can be further metabolized in liver via phase I xenobiotic
metabolism or directly conjugated either with sulfate, glucuronide, or amino acids such as glycine and excreted in urine (phase II). When FA is
absorbed from the upper parts of the intestine the main metabolites found in urine are ferulic acid sulfate (f), and feruloylglycine (g). When
dietary FA is mainly bound to AX-fibre matrix the main urine metabolites are hippuric acid (h), DHPPA sulfate (i), and HPPA sulfate (j).
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creased two to nine-fold in urine of aleurone fed mice but
not in urine from the FA fed mice, when compared to the
HF control mice. However, very little is known about the
dicarboxylic acid group in relation to dietary intake of
wheat or grains in general.
Enzymatically processed aleurone causes increased
excretion of several nitrogen-containing metabolites
The majority of the metabolites in the cluster 3 are in-
creased in groups receiving xylanase or xylanase +feruloylesterase processed aleurone (A3 and A4), and
especially in the A4 group (Figure 2). The interesting
common feature for these metabolites is that they have
nitrogen in molecular structure and some of them share
similarities in MS/MS fragmentation with the carboxylic
or dicarboxylic acids in their main structure (Table 1).
One of the compounds in this cluster (m/z 320.0436)
formed MS/MS fragment ions of m/z 150.0557 and
108.044 (Figure 7B). The fragment ion 150.0557 corre-
sponds to hydroxyphenylacetamide and 108.044 to its
basic core structure aminophenol (150.0557 – C2H2O)
Figure 6 Excretion of dicarboxylic acids in urine of mice fed diets with free commercial ferulic acid (FA), different aleurone
preparations (A1-A4), or with high-fat control diet (HF). 1. 2-oxoglutaric acid, 2. tentative 3-oxoglutaric acid, 3. malic acid, 4. 3-hydroxy-3-methyl-
glutaric acid, 5. m/z 147.029, 6. m/z 159.0291, 7. m/z 175.0238. Metabolite 2 was not present neither in the urine of HF or FA fed mice.
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ally, the loss of 79.99 Da indicated that the metabolite was
sulfonated (Table 1). This metabolite is most likely deriva-
tive of hydroxyphenylacetamide sulfate (HPAA-derivative
sulfate) as the molecular ion had also a neutral loss of
90.03 Da, tentatively a loss of C3H6O3, which would
match well with the proposed structural configuration
[41]. HPAA is a conversion product of metabolites be-
longing to the benzoxazinoid class that has recently
been described as a phytochemical group found in rye
and wheat brans [42]. The highest concentrations ofFigure 7 3,5-DHBA sulfate (A) and a conjugate of hydroxyphenylacet
MS/MS fragmentation spectra are shown for the both metabolites.benzoxazinoids are found in germ of the grain, while
the aleurone and seed coat layers are the second most
abundant [43]. The gastrointestinal metabolism of ben-
zoxazinoids is not yet described, but it has been re-
ported that phenylacetamides, which can be derived
from the benzoxazinoids are accumulating in urine [40]
and plasma (Hanhineva et al., unpublished) in humans
after rye rich diet. In addition to the HPAA-derivative
sulfate, a further degraded form, namely 2-aminophenol
sulfate (cluster 2) was also found to be excreted in urine
only after addition of aleurone into the diet, and hasamide sulfate (B) after aleurone addition into the diet. The ESI(−)
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urinary biomarker [15].
The cluster 3 included also a metabolite feature with
m/z of 232.9762 that was only detected in the urine of
aleurone-receiving groups (Fragmentation pattern in
Figure 7A). The compound was identified as 3,5-DHBA-
sulfate based on comparison with unconjugated standard
compound and on the fragmentation pattern published
earlier [17]. 3,5-DHBA is derived from the phenolic phyto-
chemical group of alkylresorcinols, a known biomarker of
whole grain wheat and rye intake [44,45]. Alkylresorcinols
have been shown to be mainly located in other parts of
the grain than in aleurone [46]. The native aleurone used
in our work has the purity degree of 85%, and it contained
therefore also a small amount of other parts of the
grain, which can be the source for the alkylresorcinols
(1.74 mg/g, data not shown), and which may explain the
urinary excretion of this biomarker.Relation to the findings in mice bodyweights and glucose
metabolism
The physiological responses of the different aleurone
preparations (A1 to A4 and commercial FA) are described
in the first part of this study (Rosa N, Pekkinen J, Zavala
K, Fouret G, Ayhan Kormaz A, Feillet-Coudray C, Atalay
M, Hanhineva K, Mykkänen H, Poutanen K, Micard V:
Enzymatic modification of wheat aleurone reduces body
weight and metabolic risk factors of obesity in mice fed a
high-fat diet. Submitted). The mice on a diet containing
enzymatically modified aleurone preparation (A4 diet) re-
duced body weight (−33%), adiposity (−16%), and fasting
plasma levels of leptin (−44%) (p = 0.0185, t-test) and insu-
lin (−30%) (p = 0.0732, t-test) when compared to HF con-
trol group (Rosa N, Pekkinen J, Zavala K, Fouret G, Ayhan
Kormaz A, Feillet-Coudray C, Atalay M, Hanhineva K,
Mykkänen H, Poutanen K, Micard V: Enzymatic modifica-
tion of wheat aleurone reduces body weight and metabolic
risk factors of obesity in mice fed a high-fat diet. Sub-
mitted). Mice fed the diet supplemented with free FA
had also significantly reduced fasting insulin levels (−35%)
(p = 0.037, t-test), but no difference in the bodyweight or
in the amount of adipose tissue as compared to the mice
fed HF diet. In contrast, the diet with ultra-fine ground
aleurone fraction (A2) resulted in increased weight gain
(+9%), adiposity (+9%), and fasting plasma insulin levels
(+22%) when compared to HF control group (Rosa N,
Pekkinen J, Zavala K, Fouret G, Ayhan Kormaz A, Feillet-
Coudray C, Atalay M, Hanhineva K, Mykkänen H,
Poutanen K, Micard V: Enzymatic modification of wheat
aleurone reduces body weight and metabolic risk factors
of obesity in mice fed a high-fat diet. Submitted). It is in-
teresting to note that the physiological responses consid-
ered beneficial were most pronounced in mice receivingthe A4 diet, which contained mainly all of the FA in its
free/soluble form.
However, according to the results from the present
study the improvements in the health status of the mice
fed with A4 diet cannot be explained by the content of
FA and its major metabolites solely, as the beneficial
effects in the FA group were limited to improved glu-
cose metabolism, and not to other measured biomarkers
including fasting leptin levels. The A4 diet contained
numerous other aleurone-bound phytochemicals that
were potentially released in the processing and were
increased in urine of mice on the A4 diet. However, ma-
jority of these metabolites were unidentified, but those
could play a role in the physiological response observed
in the A4 group mice. The A4 diet presented also a high
amount of soluble AX oligomers, due to the xylanase
treatment, which could further induce prebiotic effects
as these AX oligomers are known to be selectively fermen-
ted by the colonic microflora [47-50], and therefore the
observed effects could be also mediated via modulation of
microbiota composition.
Conclusion
It was shown for the first time that changes in the struc-
ture of the wheat aleurone matrix, without altering the en-
ergy or macronutrient content, can affect the metabolic
fate of various phenolic compounds and other phyto-
chemicals. We demonstrated differential urinary metabol-
ite profiles in a diet-induced obese mice fed chemically
similar but structurally different aleurone preparations.
The increase in free FA in the aleurone matrix resulting
from the enzymatic processing caused increased excretion
of main FA metabolites including sulfonated FA and feru-
loylglycine. However, when FA was bound to the insoluble
arabinoxylan fibre matrix as in the case of native aleurone
and cryo-ground aleurone layers, mostly microbially fer-
mented FA metabolites were found in urine. Furthermore,
the inclusion of aleurone to the diet in any form resulted
in specific fingerprint on the metabolite profile including
benzoxazinoid derivatives and alkylresorcinol metabolite
3,5-DHBA. Beneficial health effects, namely reduced body
weight, adiposity, fasting leptin levels, and improved glu-
cose metabolism, were observed predominantly in the
mice fed the enzymatically processed aleurone, but not
the pure FA group, suggesting that combined action of
readily bioavailable FA and the other aleurone released
metabolites are behind the bioactivities leading to these
beneficial effects. Overall, the results indicate that partial
depolymerization of the cell wall matrix of the wheat
aleurone might be favorable for their metabolism. There-
fore, in further studies structural features of grain ingredi-
ents should be considered in addition to their chemical
composition, as they might explain some of the variation
in human studies with this type of ingredients.
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Additional file 1: Figure S1. Shows the MS/MS spectra for tentatively
identified vanillic acid sulfate m/z 246.9918 with retention time 0.99 min.
The identification was based on comparing the MS/MS spectra with the
MS/MS spectra of standard compounds vanillic acid and DOPAC (both
unconjugated), and to the suggested fragments for DOPAC sulfate and
vanillic. Figure S2. The fragmentation pattern of tentatively identified
sinapic acid sulfate with m/z 305.0386. The identification is based on
matching molecular formula and the MS/MS fragmentation pattern acid
found in the existing literature.
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